These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 12052563

  • 1. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa.
    Price BM, Barten Legutki J, Galloway DR, von Specht BU, Gilleland LB, Gilleland HE, Staczek J.
    FEMS Immunol Med Microbiol; 2002 Jun 03; 33(2):89-99. PubMed ID: 12052563
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa.
    Gilleland HE, Gilleland LB, Staczek J, Harty RN, Garcia-Sastre A, Engelhardt OG, Palese P.
    Behring Inst Mitt; 1997 Feb 03; (98):291-301. PubMed ID: 9382753
    [Abstract] [Full Text] [Related]

  • 6. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
    Hassan R, El-Naggar W, Abd El-Aziz AM, Shaaban M, Kenawy HI, Ali YM.
    J Microbiol Immunol Infect; 2018 Jun 03; 51(3):312-320. PubMed ID: 28291719
    [Abstract] [Full Text] [Related]

  • 7. A DNA vaccine encoding VP22 of herpes simplex virus type I (HSV-1) and OprF confers enhanced protection from Pseudomonas aeruginosa in mice.
    Yu X, Wang Y, Xia Y, Zhang L, Yang Q, Lei J.
    Vaccine; 2016 Aug 17; 34(37):4399-405. PubMed ID: 27449680
    [Abstract] [Full Text] [Related]

  • 8. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
    Mansouri E, Blome-Eberwein S, Gabelsberger J, Germann G, von Specht BU.
    FEMS Immunol Med Microbiol; 2003 Jul 15; 37(2-3):161-6. PubMed ID: 12832120
    [Abstract] [Full Text] [Related]

  • 9. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
    Weimer ET, Ervin SE, Wozniak DJ, Mizel SB.
    Vaccine; 2009 Nov 12; 27(48):6762-9. PubMed ID: 19744586
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.
    Arnold H, Bumann D, Felies M, Gewecke B, Sörensen M, Gessner JE, Freihorst J, von Specht BU, Baumann U.
    Infect Immun; 2004 Nov 12; 72(11):6546-53. PubMed ID: 15501786
    [Abstract] [Full Text] [Related]

  • 12. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.
    Weimer ET, Lu H, Kock ND, Wozniak DJ, Mizel SB.
    Infect Immun; 2009 Jun 12; 77(6):2356-66. PubMed ID: 19349426
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht B, Knapp B, Hungerer K, Lücking C, Schmitt A, Domdey H.
    J Biotechnol; 1996 Jan 26; 44(1-3):145-53. PubMed ID: 8717398
    [Abstract] [Full Text] [Related]

  • 16. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.
    Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, Hackett NR, Roelvink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG.
    J Clin Invest; 2005 May 26; 115(5):1281-9. PubMed ID: 15841217
    [Abstract] [Full Text] [Related]

  • 17. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
    Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M, Takase K, Matsumoto T, Okuda K, Ishii N, Yamaguchi K, Klinman DM, Xin KQ, Okuda K.
    Vaccine; 2006 Sep 11; 24(37-39):6240-9. PubMed ID: 16806598
    [Abstract] [Full Text] [Related]

  • 18. A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection.
    Staczek J, Gilleland HE, Gilleland LB, Harty RN, García-Sastre A, Engelhardt OG, Palese P.
    Infect Immun; 1998 Aug 11; 66(8):3990-4. PubMed ID: 9673294
    [Abstract] [Full Text] [Related]

  • 19. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
    Baumann U, Göcke K, Gewecke B, Freihorst J, von Specht BU.
    Respir Res; 2007 Aug 05; 8(1):57. PubMed ID: 17683588
    [Abstract] [Full Text] [Related]

  • 20. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From Pseudomonas aeruginosa Acute Murine Pneumonia.
    Sen-Kilic E, Blackwood CB, Boehm DT, Witt WT, Malkowski AC, Bevere JR, Wong TY, Hall JM, Bradford SD, Varney ME, Damron FH, Barbier M.
    Front Immunol; 2019 Aug 05; 10():2497. PubMed ID: 31708925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.